Javara Secures Series C Funding To Drive Therapeutic Expansion For Community-Forward Clinical Research

Javara获得C轮融资，推动以社区为导向的临床研究的治疗扩展

WINSTON-SALEM, N.C., May 28, 2025-- Javara, a leading integrated research organization (IRO) delivering clinical trials at the point of care through strategic partnership with healthcare organizations, today announced it has secured a significant growth investment in Series C funding from earlier and new community-based investors..

北卡罗来纳州温斯顿-塞勒姆，2025年5月28日——Javara是一家领先的综合研究组织（IRO），通过与医疗机构的战略合作，在诊疗点开展临床试验。该公司今天宣布，已获得来自早期和新社区投资者的C轮融资，这是一笔重要的增长投资。

This funding will support the expansion of both current and new healthcare partnerships and allow the company to grow into new therapeutic specialties such as Oncology, CNS, and Neurology through localized clinical research collaborations that increase patient access and amplify geographic footprint..

这笔资金将支持当前和新的医疗保健合作伙伴关系的扩展，并通过本地化的临床研究合作，让公司能够进军肿瘤学、中枢神经系统和神经学等新的治疗领域，增加患者获取渠道并扩大地理覆盖范围。

Established in 2018, Javara was built with a vision to revolutionize the industry by accelerating access to research – for patients, biopharma companies and healthcare organizations alike. Founders Jennifer Byrne, Linda McCarty, and Amanda Wright say this funding is an essential next step in driving that mission forward..

Javara’s current access includes over 5 million patients across 7 states. The organization now faces the opportunity to double both patient and physician reach and develop new areas of therapeutic excellence that parallel current primary public health concerns and the rapid evolution of the clinical trials industry..

Javara目前的覆盖范围包括横跨7个州的超过500万名患者。该组织现在面临的机会是将患者和医生的覆盖范围增加一倍，并开发与当前公共卫生主要关注领域和临床试验行业快速演变相匹配的新的治疗卓越领域。

“We are extremely grateful for the privilege and opportunity this funding secures as we move into an accelerated growth era for Javara,” said Javara Founder and CEO Jennifer Byrne. “The support of a broadened group of community-based investors will amplify our impact greatly as we work to deliver community-based clinical trial access and education for more patients across the nation.”.

“随着Javara进入加速增长时代，我们对这笔资金所带来的特权和机会深感感激，”Javara创始人兼首席执行官詹妮弗·伯恩表示。“更广泛的社区投资者群体的支持将极大地放大我们的影响力，因为我们正努力为全国更多患者提供基于社区的临床试验机会和教育。”

Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan advised Javara on the Series C funding round.

史密斯、安德森、布朗特、多塞特、米切尔和杰尼根律师事务所为 Javara 的 C 轮融资提供了建议。

Crosstree Capital Partners acted as an advisor to Javara.

Crosstree Capital Partners 担任了 Javara 的顾问。

About Javara:

关于Javara:

Javara, the leading Integrated Research Organization (IRO), partners with large healthcare organizations to deliver clinical trial access at the point of care through integrated research staff and infrastructure. The company’s access to broad diverse patient populations through their trusted physician ensures clinical trials are completed with high enrollment and retention for quality data delivery.

Javara，领先的综合研究组织（IRO），与大型医疗保健机构合作，通过整合的研究人员和基础设施，在护理点提供临床试验服务。公司通过值得信赖的医生接触到广泛多样的患者群体，确保临床试验能够以高入组率和留存率完成，从而提供高质量的数据。

Javara’s centralized resources and standardized operations provide efficiencies for accelerated study start-up and quality outcomes, so fewer obstacles stand in the way of the product approval process. As pioneers of Clinical Research as a Care Option (CRAACO), Javara is transforming healthcare and changing lives by connecting the right patients to the right trials at the right time..

Javara的集中资源和标准化操作为加速研究启动和高质量成果提供了效率，从而在产品审批过程中减少了障碍。作为“临床研究作为一种护理选择（CRAACO）”的先驱，Javara通过在合适的时间将合适的患者与合适的试验联系起来，正在改变医疗保健并改善生活。

Contact:

联系人：

Javara Media Contact:

Javara 媒体联系人:

Genevieve Britton

日内维芙·布里顿

Genevieve.britton@precisionaq.com

吉纳维芙·布里顿@精密AQ.com